How does IDEAL work?
You can help us to bring the next breakthrough treatment to patients
At Debiopharm, our development of innovative therapies targeting unmet medical needs in oncology starts by evaluating external innovation from multiple institutions worldwide. Our desire is to better leverage the potential in our local environment, the Lemanic region of Switzerland, to provide more therapeutic innovation by building a solid life science ecosystem that connects public institutions and private companies. We believe that working hand-in-hand with institutions in the region will lead to tomorrow’s solutions for patients worldwide.
If you have a promising early-stage oncology or anti-infective compound, you can send us your project proposal for review by our Steering Committee. If your project is selected for IDEAL funding, a research and development plan will be defined, allowing you access Debiopharm’s resources and expertise.
At the end of your project, a final report of your research and results will be sent to the Steering Committee for evaluation. The Steering Committee might ask for additional information or might request a to have further discussion:
- For programs that could advance to become a Debiopharm development program, Debiopharm will communicate within 4 weeks its interest in continuing the project and will enter into negotiation for a partnership through license or research collaboration.
- If the Steering Committee decides on the basis of the results that there will be no future development by Debiopharm (Debiopharm International SA and/or Debiopharm Research & Manufacturing), the Steering Committee will issue a negative decision, which releases the institute and the researcher from their obligations.